HOME >> MEDICINE >> NEWS
Follow-up care for breast cancer patients is 'devalued and deregulated'

Follow-up of breast cancer patients after their initial treatment is becoming "devalued and deregulated", according to new research published online in the cancer journal, Annals of Oncology, today (Thursday 24 May). [1]

Yet, the authors say that if follow-up was well designed, co-ordinated and made better use of community-based teams of doctors and nurses, then health authorities could make large financial savings that could be put towards giving patients better access to new and expensive adjuvant drugs (such as aromatase inhibitors), as well as enabling them to see relevant hospital specialists more quickly. Cancer specialists would gain more time to concentrate on patients with more complex needs, while patients would gain better care and psychological support in their local communities.

Peter Donnelly, the lead author of the study, is a consultant surgeon at Torbay Hospital, UK, and a member of the Breast Cancer Studies Group of the National Cancer Research Institute (NCRI), which initiated the study in conjunction with groups involved in the development of primary care. He said: "While this research looked at what is happening in the UK, its conclusions that good follow-up is important, is more complex than previously thought and requires careful planning and co-ordination between hospitals and community-based healthcare teams, are applicable in many other countries."

The researchers found that only nine percent of cancer specialists discharged patients according to protocols that conformed with guidelines from NICE (the UKs National Institute for Health and Clinical Excellence), the duration of follow-up by the specialists ranged between a year to more than ten years in some cases, and the frequency of mammographies for invasive and non-invasive disease varied between one and three years.

Specialists cited lack of confidence in general practitioners experience and training in oncology and loss of data on patient outc
'"/>

Contact: Emma Mason
wordmason@mac.com
44-077-112-96986
European Society for Medical Oncology
23-May-2007


Page: 1 2 3 4

Related medicine news :

1. Follow-up endoscopic surveillance in colorectal cancer patients improves survival
2. Follow-up study shows drug slows severe Alzheimers symptoms for one year
3. Survival differences by race most apparent in advanced stages of breast cancer
4. Regulator of lipid metabolism ensures high quality breast milk
5. MRI finds breast cancer before it becomes dangerous
6. New cause of tamoxifen resistance in breast cancer cells discovered at Lombardi
7. Pathway links inflammation, angiogenesis and breast cancer
8. Using MRI for diagnosis could help prevent breast cancer progression
9. Speeding up CT scans with cellphone technology, ultrasound warning signal for breast cancer
10. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer
11. Dartmouths alternative breast imaging techniques sort abnormal from normal tissue

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Follow care for breast cancer patients devalued and deregulated

(Date:5/24/2013)... (PRWEB) May 24, 2013 Today marks ... all-new online Itinerary Builder. , The redesigned and ... create unique vacation itineraries on their computer or mobile ... , The interactive tool allows users to fill in ... browse through and select their choice of vacation packages, ...
(Date:5/24/2013)... American Fork, Utah (PRWEB) May 24, 2013 ... several years now and is excited to announce it’s new weight ... our product that we are offering our customers their money back ... says Dave Sherwin, CEO of HCG EZ Drops. “The HCG ... caloric intake; hence the 21 pounds in 21 days.” , The ...
(Date:5/23/2013)... Magnatag’s new magnetic 365-Day attendance and vacation monitor ... A Manufacturing Manager from Augusta GA told us, “We ... managers can check the board for themselves and we ... us and the board makes the record public so ... it has made a difference.” , “Our customers ...
(Date:5/23/2013)... FL (PRWEB) May 24, 2013 Internationally ... coaching educators in tennis for over 29 years, ... than 50 ATP & WTA players, Grand Slam winners, ... Italian Open Champions, 25 USTA National Junior Champions, 8 ... Junior Champions, including Sunshine Cup, Orange Bowl and Eddie ...
(Date:5/23/2013)... Orange County film studio and visual effects ... light leaks for Apple's Final Cut Pro X today. ... no longer have to worry about matching up the movement ... Said Christina Austin, CEO of Pixel Film Studios, "You have ... look." , ProLeak from Pixel Film Studios allows users to ...
Breaking Medicine News(10 mins):Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2Health News:Internationally Respected Tennis Coach, Nick Saviano Opens Summer Training Registration 2Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2
(Date:5/23/2013)... TEL AVIV, Israel , May 23, 2013 ... of BrainTech Israel 2013 , Israel,s ... take place on October 14 th -15 th in ... 2 nd most innovative city in the world by ... the "Start-up Nation." BrainTech Israel 2013 will showcase ...
(Date:5/23/2013)... 23, 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... of David A. Ramsay ... recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and his ... in our commercial group for the last four ...
(Date:5/23/2013)... 2013  Omeros Corporation (NASDAQ: OMER ... Application (IND) to evaluate OMS824 in Huntington,s disease ... Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 ... brain linked to a wide range of diseases ... OMS824 has shown promising results in animal models ...
Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4
Cached News: